10-year follow-up after interferon-α therapy for chronic hepatitis C

Hepatology

Volumn 28, Issue 4 I, 1998, Pages 1121-1127

  Lau, Daryl T Y ^a   Kleiner, David E ^b   Ghany, Marc G ^a   Park, Yoon ^c   Schmio, Peter ^d   Hoofnagle, Jay H ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d National Genetics Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; AMINOTRANSFERASE; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; BIOPSY; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER; MALE; MIDDLE AGED; PILOT PROJECTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SURVIVORS; TIME FACTORS;

EID: 0031704927     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510280430     Document Type: Article

References (32)

1. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975;292:767-770.
2. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
3. Kuo G, Choo Q-L, Alter HJ, Gitnick GL, Redeker AG, Purcell H, Miyamura T, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B antibodies. Science 1989;244:362-364.
4. Weiner AJ, Kuo G, Bradley DW, Bonino F, Saracco G, Lee C, Rosenblatt J, et al. Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet 1990;335:1-3.
5. McQuillan GM, Alter MJ, Mover LA, Lambert SB, Margolis HS. A population based serologic study of hepatitis C virus infection in the United States. In: Rizzetto M, Purcell RH, Gerin JL, Verme G, eds. Viral Hepatitis and Liver Disease. Turin: Edizioni Minerva Medica, 1997:267-270.
6. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. HEPATOLOGY 1997;26(Suppl.):15S-20S.
7. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. HEPATOLOGY 1997;26(Suppl.):34S-38S.
8. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha-interferon. N Engl J Med 1986;315:1575-1578.
9. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
10. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
11. Marcellin P, Boyer N, Giostra E, Degott C, Couroucé AM, Degos F, Coppere H, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. HEPATOLOGY 1991;13:601-603.
12. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. HEPATOLOGY 1996;24:778-789.
13. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. HEPATOLOGY 1992;15:1013-1016.
14. Fong T-L, Shindo M, Feinstone SM, Hoofnagle JH, DiBisceglie AM. Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C. J Clin Invest 1991;88:1058-1060.
15. National Institutes of Health Consensus Development Conference Panel. Statement: management of hepatitis C. HEPATOLOGY 1997;26(Suppl.):2S-10S.
16. Nolte FS, Thurmond C, Fried MV. Pre-clinical evaluation of Amplicor hepatitis C virus test for detection of hepatitis C virus RNA. J Clin Microbiol 1995;33:1775-1778.
17. Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. HEPATOLOGY 1997;26:1640-1645.
18. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-1102.
19. Simmonds P, Rose K, Graham S, Chan S-N, McOmish F, Dow B, Follett E, et al. Mapping of serotype-specific epitopes in the NS4 region of hepatitis C virus (HCV) : use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3. J Clin Microbiol 1993;31:1493-1503.
20. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY 1994;19:1513-1520.
21. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdayin C, Swain M, et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903.
22. Fong T-L, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. HEPATOLOGY 1993;18:1313-1318.
23. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, Di Napoli A, et al. Long-term follow up of patients with chronic hepatitis C treated with different doses of interferon-α 2b. HEPATOLOGY 1993;18:1300-1305.
24. Shindo N, Arai K, Sokawa Y, Okuno T. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-α therapy. Ann Intern Med 1995;122:586-591.
25. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med 1997;127:875-881.
26. Cammà C, Di Marco V, Lo lacono O, Almasio P, Giunta M, Fuschi P, Vaccaro A, Fabiano C, Magrin S, Di Stefano R, Bonura C, Pagliaro L, Craxi A. Long-term course of interferon-treated chronic hepatitis C. J Hepatology 1998;28:531-537.
27. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of alfa-2b trials. HEPATOLOGY 1997;26(Suppl.):78S-82S.
28. Lee WM. Therapy of hepatitis C: interferon alfa-2a trials. HEPATOLOGY 1997;26(Suppl.):89S-95S.
29. Farrell GC. Therapy of hepatitis C: interferon alfa-n1 trials. HEPATOLOGY 1997;26(Suppl.):96S-100S.
30. Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, Heathcote EJ, White H, Foust RT, Jensen DM, Krawitt EL, Fromm H, Black M, Blatt LM, Klein M, Lubina J, and the Consensus Interferon Study Group. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. HEPATOLOGY 1997;26:747-754.
31. Seeff LB. Natural history of hepatitis C. HEPATOLOGY 1997;26(Suppl.):21S-28S.
32. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:H63-1466.